AVENUE THERAPEUTICS

Company snapshot

Avenue Therapeutics, Inc. (OTC: ATXI), a Fortress Biotech (NASDAQ: FBIO) subsidiary, is a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases. Please be aware of Recruiting Fraud: https://www.avenuetx.com/beware-of-recruiting-fraud/

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for AVENUE THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  CNS Pharmaceuticals

  TA overlap score 24.2

Recent activity

Latest pipeline, patent, and corporate events for AVENUE THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   Tramadol — Phase 3

2. Jun 8, 2026 Clinical update

   Artemether-lumefantrine — Phase 3

3. Jun 8, 2026 Clinical update

   Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo] — Approved

4. May 23, 2026 Clinical update

   Pyridoxal-5'-Phosphate supplement — Unknown

5. Apr 20, 2004 Patent grant

   CTL epitopes from EBV

View all clinical trial activity →

• What is AVENUE THERAPEUTICS?

  Avenue Therapeutics is a pharma organization headquartered in Bay Harbor Islands, USA. It trades on NYSE under ticker ATXI. Primary therapeutic focus areas include Acne Vulgaris, Plasmodium Falciparum Malaria, Neural Inhibition, Pain Management. NovaPharmaNews links 4 clinical pr

• Is AVENUE THERAPEUTICS publicly traded?

  Yes. AVENUE THERAPEUTICS is listed with ticker ATXI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does AVENUE THERAPEUTICS develop or market?

  We link 8 drug profile(s) where AVENUE THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/avenue-therapeutics-inc#company-drugs.

• What are the latest developments for AVENUE THERAPEUTICS?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AVENUE THERAPEUTICS focus on?

  AVENUE THERAPEUTICS focuses on Acne Vulgaris, Plasmodium Falciparum Malaria, Neural Inhibition based on our analysis of their pipeline programs and drug development activities.